OneOncology Presents Abstracts at ASCO Highlighting Importance of Increasing NGS Testing

Research Presented by Dr. Thomas Stricker Suggests Oncologists Should Switch to Targeted Treatment if Biomarker Testing Identifies Actionable Mutation Even After First-Line Treatment on Non-targeted treatment Has Begun Research Led by Dr. Gregory Vidal Evidences Identifies Inequities by Community Practice and Provider Levels in Accessing NGS Testing Among Black and Latinx Patients NASHVILLE, Tenn., May … Read more